30.15
Schlusskurs vom Vortag:
$30.42
Offen:
$30.23
24-Stunden-Volumen:
669.84K
Relative Volume:
0.67
Marktkapitalisierung:
$2.77B
Einnahmen:
$4.72M
Nettoeinkommen (Verlust:
$-277.91M
KGV:
-8.0831
EPS:
-3.73
Netto-Cashflow:
$-203.56M
1W Leistung:
+1.24%
1M Leistung:
-12.41%
6M Leistung:
-48.64%
1J Leistung:
-29.83%
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Firmenname
Crinetics Pharmaceuticals Inc
Sektor
Branche
Telefon
858-450-6464
Adresse
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
Vergleichen Sie CRNX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CRNX
Crinetics Pharmaceuticals Inc
|
30.15 | 2.77B | 4.72M | -277.91M | -203.56M | -3.73 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-25 | Eingeleitet | Stifel | Buy |
2025-02-11 | Eingeleitet | TD Cowen | Buy |
2025-02-04 | Eingeleitet | Wolfe Research | Peer Perform |
2025-01-22 | Hochstufung | Jefferies | Hold → Buy |
2024-03-06 | Eingeleitet | Citigroup | Buy |
2024-01-16 | Eingeleitet | Morgan Stanley | Overweight |
2023-12-21 | Eingeleitet | Jefferies | Hold |
2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2023-08-31 | Eingeleitet | Oppenheimer | Outperform |
2023-04-24 | Eingeleitet | Piper Sandler | Overweight |
2023-03-30 | Eingeleitet | Robert W. Baird | Outperform |
2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
2021-11-23 | Eingeleitet | Evercore ISI | Outperform |
2021-06-18 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-12-23 | Eingeleitet | ROTH Capital | Buy |
2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
2018-08-13 | Eingeleitet | JP Morgan | Neutral |
2018-08-13 | Eingeleitet | Leerink Partners | Outperform |
2018-08-13 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Wells Fargo & Company MN Increases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Invesco Ltd. Acquires 42,954 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Russell Investments Group Ltd. Sells 43,501 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Affinity Asset Advisors LLC - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh Gottheimer - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Alliancebernstein L.P. - Defense World
JPMorgan Chase & Co. Has $13.78 Million Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
Key Investor Alert: Crinetics Sets Date for Crucial Q1 2025 Financial Results - Stock Titan
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants - GuruFocus
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Acromegaly Pipeline 2025: Detailed Clinical Trials - openPR.com
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Growth Signal: Crinetics Awards Major Equity Package in Latest Hiring Wave - Stock Titan
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Sei Investments Co. - Defense World
Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA - Seeking Alpha
CRNX stock touches 52-week low at $31.81 amid market challenges - Investing.com
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation Of Marketing Authorization Application (MAA) And Orphan Drug Designation (ODD) For Paltusotine In Acromegaly - MarketScreener
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug - Marketscreener.com
Breakthrough: First Oral Acromegaly Drug Hits Major EU Milestone with Dual Regulatory Wins - Stock Titan
Crinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by Stifel Nicolaus - Defense World
Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology - Benzinga
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation - Nasdaq
Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target - Marketscreener.com
Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, - openPR.com
(CRNX) Trading Report - news.stocktradersdaily.com
Connor Clark & Lunn Investment Management Ltd. Sells 13,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Proficio Capital Partners LLC Purchases Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock By Investing.com - Investing.com Australia
Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock - Investing.com Australia
Crinetics Stock: Executives Sell Shares Amid Analyst Optimism - sharewise.com
Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 By Investing.com - Investing.com Australia
Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock - Investing.com India
Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 - Investing.com
Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock - Investing.com
CRNX News Today | Why did Crinetics Pharmaceuticals stock go down today? - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
US Bancorp DE Sells 5,176 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Where are the Opportunities in (CRNX) - Stock Traders Daily
Will Crinetics Pharma's Upcoming Events Drive Stock Momentum? - RTTNews
Bank of New York Mellon Corp Has $17.63 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Crinetics Pharmaceuticals Grants Stock Options and RSUs to New Employees Under 2021 Inducement Plan - Nasdaq
Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):